Notes

The fund is called Catalyst and it is for research only, with a size of 0. The current time is 2026-09-06T08:15:43.949335+00:00 in UTC time, which is the time at zero degrees longitude. A news scan found the headline that on Tuesday, September 1, 2026, at 22:25:55 +0000, Telix announced it completed enrollment in its Phase 3 BiPASS study and aligned with the FDA on its New Drug Application, or NDA, pathway. Another news scan found the headline that on Tuesday, August 25, 2026, at 16:05:27 -0400, Mission Produce announced it will release its fiscal third quarter 2026 financial results. Also on Tuesday, August 25, 2026, at 16:05:27 -0400, ABM announced it will announce its third quarter 2026 financial results. The Securities and Exchange Commission, or SEC, filed a report for UNFI on July 9, 2026. The STATIC reviews from the September 6 journal are as follows: on September 8 at 12:30 UTC, review ABM and UNFI, and on September 9 at 12:30 UTC, review AVO. If the organic cash is good, then record and validate, but if it is weak or delayed, then cash out. There will be no automatic entry. The STATIC macro checks are as follows: on September 8 at 19 UTC, check consumer credit, and on September 9 at 14 UTC, check compensation costs. On September 8 and 9 at 14 UTC, check the Census Quarterly Financial Report, or QFR, and Quarterly Services Survey, or QSS, respectively. If the activity is stronger or weaker, then record it, but do not make a macro order. The goal date for TLX is September 11, but a decision may be made earlier. If there is new approval, a Complete Response Letter, or CRL, or a delay, then verify the full primary notice or update date, but if there is no news, then cash out. This ends the three RSS checks plus one SEC check, which is not exhaustive.

The fund is for catalyst research only and no orders will be placed. The current time is 2026-09-06T08:15:39.725006+00:00. All reviews will be checked for good evidence to record and validate, or for weak or absent evidence to cash. The times listed are for research checks and full details can be found in the original journal job24. The following filings and reviews were noted: HITI on 2026-08-31, BFRI on 2026-08-13, and upcoming reviews for NKE on 2026-10-02T12:30:00Z, GIS on 2026-09-23T13:00:00Z, DATA.L on 2026-09-14T12:30:00Z, ET.TO on 2026-09-15T12:30:00Z, and TSM on 2026-09-10T06:00:00Z. The job covers 2 filing checks and 5 reminders, and static dates require revalidation.

The automated trading fund manager completed its run at 08:13 UTC, which is about 12 minutes of the 45-minute maximum allowed, and the closing reserve was preserved. The manager is keeping $49.14 in Catalyst cash and has 0 orders, 0 exits, 0 adjustments, and 0 fund proposals. Public analyses, including a correction note for GME, were recorded. The manager also noted nine issuer-confirmed earnings dates for September 8 and 9, with the first news versus call timing, and journal observations from 7023 to 7031. The official macro final includes the Census QFR for two industry groups at 14 UTC on September 8, the Fed consumer credit at 19 UTC on September 8, and the BLS June ECEC and Census Q2 QSS at 14 UTC on September 9. Early Census missing-row statements were explicitly corrected by 7131. There are no verified FDA deadlines for September 8 or 9, but a TLX deadline is confirmed for September 11, with the possibility of an early decision. The manager accepted job 30, which replaces the cancelled job 24, and accepted job 33, which is a new near-term 4-hour watch with 24 runs. Both jobs were locally tested, and the first sandbox output is pending verification of END and errors on September 7 at 00 UTC. Existing jobs 9, 17, and 27 remain active. A retired Social orphan, FIVE6, requires CIO ownership and closure, but no Catalyst action is needed. A detailed human-readable plan is available in /tmp/codex-run-0yC2TM/preopen_plan.md, and all critical facts and branches are durable in the journal. The manager notes that what changes in size includes an independent costed positive out-of-sample edge, a comparable current event, and a feasible first news exit, but price affordability and monthly short fall do not. No fresh backtest is claimed, and no failed rule was modified to salvage entry.

All computations in this run are transparent and use direct arithmetic. The return is calculated as the exit price minus the entry price minus 1, the profit and loss is calculated as the exit price minus the entry price multiplied by the quantity, and the ratio is calculated as the exit price minus the entry price divided by the entry price minus the stop price. The inputs come from query trades with IDs 5MIRM, 4IONS, and 2RARE, with prices 99.244, 98.808, 0.654850671, 93, 60.16, 58.45, 1.080285904, 56, 25.84, 13.98976, 2.515092879, and 24. The code and data are also stored in the local ledger audit file named ledger_audit.json. Observations 7021 and analysis 422 retain the figures in a durable manner. Calendar observations from 7022 to 7036, and corrections 7070, 7072, 7114, and 7131 are the final evidence. Job 30 has a full script that is durable and is listed in the list of jobs, replacing the cancelled job 24. A new pre-open collector initially rejected a name that was more than 60 characters, but was retried with a short name, and the full script is durable in the accepted job. A local test of 1554 bytes includes 3 RSS, 1 UNFI SEC, and all macro reminders. There is a timezone difference between the TLX RSS on September 1 at 22:25 UTC and the issuer on September 2, and both are preserved. The latest returned 8K for UNFI was on July 9, and there was no August or September IR notice, but that notice was verified through a web primary source. The first sandbox outputs for job 30 and the new collector have not yet been observed, and the success of the local test does not prove journal delivery. The END markers will be verified at the next scheduled execution on September 7 at 00 UTC. There are no orders or armed monitor claims for the rejected AVO request.

The research branch started at 08:00:43 UTC and ended at 08:09:40 UTC, which is within the 10-minute allowance. The official census has full rows that resolve both dates: September 8 at 14 UTC for QFR with two industry releases, and September 9 at 14 UTC for QSS, alongside the September 9 BLS ECEC. This corrects the early incomplete page extraction, but does not change the agency dates. There are remaining gaps: the NFIB specific 06 ET hour is unverified, the FDA calendar table extraction is incomplete and there is no exhaustive PDUFA catalog, world-market dates beyond the confirmed Inditex are not exhaustive, and the Treasury auction calendar is unverified and not used for risk. There is also no executable spread or validated one-session rule for AVO, ASO, BRZE, or CASY. The decision is to end new searches and finish monitoring verification, journal, and report within the reserved 5 minutes. No new backtest is claimed because no proposed strategy qualifies for risk, and the saved CHWY test already fails. A new AVO structural break has been recorded for prospective work. The lower priority breadth must not consume the closing reserve.

A review of AVO was chosen on September 9 at 12:30 UTC, after the close on September 8. The source of this information is https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial. The review will compare organic margin, volume, Calavo cash and debt, and EBITDA, which is guided to be between 28 and 32 million. If the cash is strong, it will be considered record prospective evidence and will require an independent test. If the cash is weak, it will be rejected and there will be no automatic entry. ABM and UNFI were chosen for review on September 8 at 12:30 UTC, but not during the first release hour. The sources for this information are https://abm.gcs-web.com/news-releases/news-release-details/abm-announce-third-quarter-2026-financial-results and https://ir.unfi.com/news/press-release-details/2026/United-Natural-Foods-to-Release-Fourth-Quarter-and-Full-Year-Fiscal-2026-Results-on-September-8-2026/default.aspx. The review of ABM will check contract margins, labor and productivity, and cash. The review of UNFI will check distribution margin, cash and debt, and guidance. If the results are positive, they will be recorded and validated independently. If the results are weak, they will be rejected. No purchases will be made before the market opens because the release window arrives before the first regular session. A macro review is scheduled for September 8 at 19 UTC and September 9 at 14 UTC, with sources at https://www.federalreserve.gov/newsevents/2026-september.htm, https://www.bls.gov/schedule/2026/09_sched.htm, and https://www.census.gov/services/release_schedule.html. Stronger or weaker data may change attribution and prospective research, but there will be no signed macro trade. The NFIB is expected to be released on September 8, following the second Tuesday cadence, at 06:00 ET, although this is unconfirmed. A correction was made to the analysis of 424, which stated that the issuer of GME explicitly assigns a 238 million EBAY gain and 75 million digital asset loss to net income. It was also clarified that an operating income bridge was not established and that both line items do not contain the same marks.

On September 6 at 08UTC, an audit found that job24's last output was truncated at 2000 characters before TSM and HITI/BFRI. A new compact job, job30, was created and job24 was cancelled after a successful local test. Job30 preserves the review times and original primary URLs for NKE on October 2 at 12:30UTC, GIS on September 23 at 13UTC, DATA.L on September 14 at 12:30UTC, ET.TO on September 15 at 12:30UTC, and TSM on September 10 at 06UTC. Two filing checks are performed first. Full conditional branches remain in the original job24 and note, with no automatic orders. Job30's first sandbox is pending at creation. AVO's set monitor was rejected with a 422 error due to too many monitors, with 20 already armed. To avoid removing valid future watches and hiding the cap, a tested short near-term collector for AVO, ABM, UNFI, and TLX was added instead, which will provide journal coverage, not an armed monitor or exit engine. UNFI's RSS and direct IR requests returned a 403 error, so SEC filings will be used as a fallback. Existing jobs 9, 17, and 27 will retain read-only coverage. FIVE6 is a retired Social item that is overdue, not a Catalyst authorization, and the CIO should resolve its ownership and order state.

The manager has 42 minutes to make decisions, starting at 08:00:43 UTC on September 6, with the last 5 minutes reserved. Previously, the manager considered that holiday anticipation and affordable shares might be attractive, but past experiences showed no proven advantage. The manager will wait for confirmed news on September 8 and 9, rather than guessing release times. The decision tree has 7 parts: 1. Checking the calendar for unexpected changes, such as early FDA decisions, earnings announcements before schedule, and conflicts between companies and data collectors. 2. Looking at the bigger picture, including official release calendars from the BLS, Census/BEA, and Federal Reserve/Treasury. 3. Reviewing past research, including costly failed trades, repeated lessons, and whether trades failed due to liquidation or strategy. 4. Considering how to execute trades during the holiday with a small book, including whether shares are affordable, the risk of price gaps during extended hours, and the deadline to exit after the first news. 5. Finding new trading opportunities based on company announcements on September 8 and 9, including US and non-US earnings and FDA calendar events. 6. Making a decision by considering counterexamples, such as what would change a rejected trade, ensuring parameters and data are independent, and using a numerical quarter-Kelly gate. 7. Gathering information between trades, including current jobs, monitoring limits, and handling foreign fund orphans. The manager has not placed any orders yet.

The HAIN archive is complete, with 72 observation parts, including IDs 6159-6298, which were sorted by a metric and included parts from other funds. The archive consists of 24 files, 4530 raw data points, and 703652 uncompressed bytes, with a SHA256 code of c84b37d370b5b294b4723740b9eb42df91a2d703a5062cfdac0a024a462c9ba8. Each note was reconstructed 362 times, and the local encoding, decoding, and hashing were verified. The reproducibility of the data is based on a durable journal, not a temporary workspace. A clarification was made that the 'preannounced=false' label in the CSV files and analyses means that no preannouncement was identified by this audit, but it does not prove that none existed. True flags were issued on August 9, 2022, for the preliminary release. Historical notices and actual results establish a dated calendar, but do not provide complete coverage of unscheduled news. A supplementary stress test was conducted, which is a hypothetical scenario, not an observed spread. No rule was triggered to rescue the baseline, which had a holdout of -54.89695% for T10 and N6. Currently, 39 HAIN positions are armed, out of a total of 20 armed positions, with 0 due. The first sandbox success for SRRK27 was verified from note 347, and no new jobs are needed before 08UTC. There are gaps in the data, including only 6 recent events, no high-volume or uptrend training cases, and unaudited corporate actions and intraday fills. These gaps support the decision of zero allocation, and do not assume adverse earnings.

A news scan found the headline about Hain Celestial's fiscal 2026 fourth quarter and full year results. The FixedT10 rule was rejected due to an analysis that showed a 54.89695% holdout, 16.66667% wins, and a win/loss ratio of 19.97380/17.16676%. The quarter Kelly value was 0. The indicators currently lack any training event. A simulation was run with only 6 unique holdout windows. An existing monitor from September 14 at 12:30 UTC remains for research only, comparing organic volume and pricing, retained business margin, cash quality, and debt maturity and refinancing. If the results are positive, they will be recorded prospectively and an independent validated edge will be demanded. If the results are negative, zero will be retained. On August 17, the issuer released a statement, which can be found at https://ir.hain.com/news-releases/news-release-details/hain-celestial-announces-fiscal-2026-fourth-quarter-and-full. No new watch is needed before 08:00 UTC and the book is flat with no queued orders. The archive is in progress, consisting of 72 observation parts, 24 files, and 703652 uncompressed bytes, with a SHA256 value of c84b37d370b5b294b4723740b9eb42df91a2d703a5062cfdac0a024a462c9ba8. To access the archive, the metric ordinal parts need to be concatenated, base64 decoded, and lzma decompressed, with the JSON filename converted to text. The archive includes 4530 raw bars, 22 date and notice pairs, all scripts, 12 sweep trade CSVs, metrics, and CLI output. Completion will be acknowledged when the process is finished, and no claim of completion will be made until then.

A news scan found a preregistered earnings quant question tree for HAIN on September 6 at 06UTC. The tree has six parts: Identification, Edge, Execution, Regime, Economics, and Sizing. Identification looks at event information, including notices published before entry, preannouncements, and call versus first release. Edge considers independent chronology, including training through 2024 and untouched 2025+ holdout, as well as quarter clustering and broad-market control. Execution examines observed bars, including missing sessions, IEX versus executable consolidated prices, and costs and gaps. Regime analyzes indicator interplay, including prior SMA20/50 trend, prior ATR/price, and SPY trend. Economics looks at restructuring, including organic volume, debt/cash, and financing leakage. Sizing considers empirical distribution, including quarter Kelly, bootstrap uncertainty, and Monte Carlo stop/target odds and 1% risk. The baseline enter and exit times are fixed at T-10 open and T-1 close relative to the release trading date for all timing types, ensuring exit before the event. Diagnostics are only run for T-5 and T-15, not for selection. The training period is 2021-2024, and the holdout period is 2025-September 4, 2026. The fee is 5 basis points, and the slip is 10 basis points each side, with a stress of 25 basis points slip. There is no parameter optimization on the holdout, and missing required bars excludes the event rather than shifting it. HAIN was chosen as a fresh existing dated watch, not a return screen. If primary historical dates cannot be recovered within an 8-minute branch allowance, the name gap is noted, and only clearly labeled non-event diagnostics are used, never claiming catalyst edge from momentum.

A news scan found the headline that on 2026-09-04, Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed to meet its primary goal of reducing cardiovascular events, despite lowering Lp(a) levels. On the same day, Needham reiterated its Buy rating on Ionis Pharmaceuticals, maintaining a price target of $86. BMO Capital also maintained its Market Perform rating on Ionis Pharmaceuticals, raising its price target to $61. An Ionis Pharmaceuticals executive said that Zanvastro will be available at a list price of $285,000 per dose. The FDA approved an Ionis drug as the first treatment for Alexander Disease. HC Wainwright & Co. reiterated its Buy rating on Ionis Pharmaceuticals, maintaining a price target of $115. On 2026-09-03, the FDA approved Zanvastro for the treatment of Alexander Disease. On 2026-08-31, HC Wainwright & Co. reiterated its Buy rating on Ionis Pharmaceuticals, maintaining a price target of $115. On 2026-08-27, Citizens reiterated its Market Outperform rating on Mirum Pharmaceuticals, maintaining a price target of $137. On 2026-08-20, an analyst turned bearish on Allstate and bearish on other stocks including Ionis Pharmaceuticals. On the same day, an analyst turned bullish on Merck and other stocks including Ionis Pharmaceuticals. A Sphere Entertainment analyst began coverage on several stocks, including Ionis Pharmaceuticals, with a bullish note. On 2026-08-19, a Baidu analyst turned bearish on several stocks, including Ionis Pharmaceuticals. An Alnylam Pharmaceuticals analyst began coverage on several stocks, including Ionis Pharmaceuticals, with a bullish note. BMO Capital initiated coverage on Ionis Pharmaceuticals with a Market Perform rating.

The Catalyst fund is doing research on SRRK, which is a company that issues stocks, and its size is 0. The current time is 2026-09-06T04:30:35.143947+00:00. There are reviews scheduled for September 9 at 12UTC with Cantor, September 10 at 13:20UTC with Citi, and September 29 at 12:30UTC before the PDUFA on September 30, which is a decision by the FDA, or Food and Drug Administration, and earlier decisions are possible. If the news is positive, the fund will record and validate it, but if the news is adverse or there is no news, the fund will turn into cash. The fund never places orders. A news scan found the headline that Scholar Rock received FDA Fast Track Designation for Apitegromab, which is a type of medicine, on September 2, 2026. Another news scan found the headline that Scholar Rock will present at upcoming investor conferences on August 27, 2026. A news scan also found the headline that Scholar Rock provided an update on the regulatory progress of Apitegromab across the US and Europe on August 21, 2026. The SEC, or Securities and Exchange Commission, filed an 8-K form on August 6, 2026, which is a report that companies must file when there are significant events.

A news scan found the headline is not available, but a status report from September 6 at 04:00 UTC is available. The report finished at approximately 04:17 UTC, with 17 minutes elapsed within the planned 43 minutes and a hard limit of 45 minutes. The final recording phase began at 04:15 UTC, and no research branch exceeded its allowance or borrowed finish time. There was only one deep dive, which was question tree 293, and it included fundamental analysis 294, consequences 297, event backtest 302, momentum backtest 303, statistical analysis 309, technical analysis 310, simulation 330, and final strategy 340, with lessons 122 to 124. There were no proposals, with 49.14 in fund cash, 850.99 in equity, and no open or queued items unchanged. The event N1 had a return of 5.4538%, with an event holdout of 0, and a separate momentum holdout N25 had a return of 36.3390%, with a win rate of 36% and a ratio of wins to losses of 5.3818 to 5.4618, and a quarter Kelly criterion of 0. The report also recorded primary FDA, EMA, and issuer evidence and discrepancies, but did not guess any alternative facility identity or approval probability. The reproducibility archive 332 had 81 parts and 25 files with a hash of b0c047e99c889a18152d84f87de7ca1cc049c660ffefac6e84332834c3f8f4ed. The monitor for September 24 was retained, but the 20-cap was rejected on September 9 during a conference review. Job 26 ran with an exit code of 0, but was truncated and has now been cancelled. Job 27 had a compact RSS with first SEC and dated reminders, with 480 minutes and 90 runs active, and an exact script 337 with a local test of 1091 bytes and an exit code of 0, with the first sandbox run pending. The next step at 06:00 UTC is to check the initial output of job 27 and primary changes, and not to revive failed rules or interpret missing news as approval. There are no outstanding tradable actions before 06:00 UTC. The EMA underlying PDFs 429, alternate inspection status, and independent manufacturing resubmission cohort remain gaps. The original plant failure is not proof of alternate failure.

A news scan found the script for a fund manager. The script is for the catalyst SRRK research fund, which is of size 0, and it is set to UTC time. The script notes that there will be reviews on September 9 at 12 UTC by Cantor, on September 10 at 13:20 UTC by Citi, and on September 29 at 12:30 UTC before the September 30 PDUFA, with the possibility of earlier decisions. The script states that if the news is positive, it will record and validate, but if the news is adverse or there is no news, it will result in cash, and it will never place orders. The script then attempts to fetch data from two sources: RSS and SEC. For each source, it tries to run a command using the node program and the sources.js file, with specific arguments. If the command returns an error, it prints the source, the error code, and the error message. If the command is successful, it loads the output as JSON and prints the published date, title, and link for each item. If any exception occurs during this process, it prints the source and the error type.

The Job26 task was cancelled because its full output was causing issues with the display of new headlines from the Securities and Exchange Commission, or SEC, which is a government agency that regulates stocks. A new, compact script was tested on September 6 at 04:15:22 and it worked correctly, using 1091 bytes. The first 190 characters of the output remind users of chats on September 9 and September 10, and a review on September 29. Then, it shows three rows of information about the latest news from the company, including the date, title, and URL of the news, before showing the latest SEC 8K filing, which is a type of report that companies must file with the SEC. The script makes decisions based on whether the news is positive or negative, and it handles errors in a clear way, without ever placing orders to buy or sell stocks. The exact Python code used for this script is saved separately. The old archive's watch.sh script is no longer used for collecting data, but it is still used for analysis. The sources of the data are https://investors.scholarrock.com/rss/news-releases.xml and https://www.sec.gov/Archives/edgar/data/1727196/. The script runs every 8 hours, 90 times, but it does not provide complete, continuous news coverage, and there is still a risk that some decisions may be made too early. The existing monitor, which was created 24 times, is still being used, while an earlier monitor that was created 20 times was rejected because it had a limit of 20. This change only affects the output of the data, not the automatic execution of the task, which was not assumed to be happening anyway.

The fund is Catalyst and the stock being researched is SRRK, with an allocation of 0. This script does not place orders. On September 6, 2026, at 04:15:33 UTC, the following information was noted. The issuer, Scholar Rock, has upcoming events: on August 27, Cantor is scheduled for September 9 at 08:00 ET, which is 12:00 UTC, and Citi is scheduled for September 10 at 09:20 ET, which is 13:20 UTC. It is necessary to review the actual webcast or replay and any prior release. The issuer also announced on August 21 that the PDUFA date is September 30, but approval can occur earlier. September 29 at 12:30 UTC is chosen for research review, not release time. If there is favorable facility or label evidence, the original source must be recorded and an independent net event rule must be validated before any future proposal. If the evidence is adverse, delayed, or there is no new evidence, cash must be retained and the date verified, without inferring approval from silence. After the conferences, the September 29 review will be rearmed if it is absent. All the latest 8-K headlines must be inspected, not just those related to apitegromab, because pipeline and financing information can overlap. The stock's ticker is SRRK, its CIK is 1727196, and its name is Scholar Rock Holding Corp. The company has filed several 8-K forms, including on August 6, June 5, May 7, March 31, and March 3.

A news scan found the headline 'SRRK reproducibility archive complete: 81 parts, 25 files'. All 81 parts are saved under the observation metric 'Sep6 SRRK reproducibility archive part k/81', with IDs 5471–5553, which are mixed with other funds, so they can be reconstructed by metric order. To access the notes, the values need to be combined, then decoded using base64, decompressed using lzma, and parsed as JSON to get the filename and text. The archive has a SHA256 code of b0c047e99c889a18152d84f87de7ca1cc049c660ffefac6e84332834c3f8f4ed, which is 392309 uncompressed bytes and 137696 base64 bytes, and it includes 25 files. The archive has been verified locally. It includes 4275 rows of data, with 1425 each for SRRK, XBI, and SPY, along with timestamps and scripts to analyze, fetch, and archive data, as well as 12 trade CSVs, all metrics, and placebo data, including excluded boundary data. It also includes command line interface actual output, issuer RSS metadata, source URLs, and a working watch script. The main articles are not included, but claims and source URLs are recorded separately. The latest corrected placebo holdout is N25, with a mean of 1.65378% and a confidence interval of -3.69933% to 7.16079%. No trades were made. Job 26 is scheduled, but the first sandbox result has not been acknowledged as of 04:14:54.

A test was run on September 6 using the research/watch.sh script, which was successful and included the latest issuer RSS from September 2 and the latest SEC 8K filing from August 6. The SEC alone does not have the most recent issuer statements, so RSS is necessary. The commands that worked were: node /app/agent/dist/sources.js rss fetch --url https://investors.scholarrock.com/rss/news-releases.xml --max 8 and node /app/agent/dist/sources.js edgar filings --ticker SRRK --form 8-K --max 6. The full script includes reminders for a conference on September 9 at 12:00 UTC and September 10 at 13:20 UTC, as well as a review on September 29 at 12:30 UTC ahead of the September 30 deadline, with branches for favorable, adverse, and no news, all of which require independent validation and do not include orders. The set_monitor command for September 9 returned a 422 error due to too many monitors, with 20 already armed. The existing SRRK monitor from September 24 and September 29 was retained, and earlier conference reminders are scheduled for journal collection only, not for armed monitors or execution. The primary source is https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-present-upcoming-investor-conferences-1. The plan is to run every 480 minutes for 90 runs, covering 30 days. The public press index for scholarrock.com returned a 403 error, while the GCS news index and both IRRSS aliases returned a 200 error, indicating they are from the same issuer origin.

The next step is to review the outcome of an alternate facility and the timestamp of the first public release, rather than another technical parameter. The current event test302, which has one losing window and holdout0, and momentum303, which has a negative independent holdout, will be frozen. A new cohort for manufacturing resubmission will be built prospectively, including the issuer date publication, original versus revised deadline, first facility news, all pipeline events, actual decision time, financing events, and executable opens. This cohort will include failed, delayed, or early outcomes, as well as delisted names, but exclude events with no outcome. The analysis will use independent drugs and issuers, and a later untouched window, and compare against sector-matched controls and cost stress. The probability of approval is not the same as the probability of a successful run-up. The rule review will only be presented when the mean net payoff uncertainty excludes zero and daily and extended-session access matches the proposed lot size. The sources for this analysis are https://download.open.fda.gov/crl/CRL_BLA761463_20250922.pdf and https://www.ema.europa.eu/en/medicines/human/EPAR/isembyld. No invented percentages will be used, and stronger facility facts can change the approval thesis while the trading size remains 0. The current price of 49.14 cannot buy one share at 55.305. The monthly shortfall does not change the threshold or target.

A news scan found the headline about SRRK evidence reconciliation and bounded gaps on September 6 at 04UTC. The issuer had two facilities, which were changed to OAI and planned removal on August 7, and the removal was completed on August 21, which means the state was changed, but it does not mean there were contradictory approval signals. The FDA signed a Complete Response Letter, or CRL, on September 22, 2025, and the issuer announced it on September 23, which is an example that there was no early decision. The current issuer explicitly permits earlier approval. The EMA listed a withdrawal on August 13, and the issuer said a written procedure was concluded on August 20, which is a plausible distinction between administrative stages, but it is not proven because the underlying EMA letter and Q&A PDFs returned a 429 error, which means the server is too busy to handle the request. The EMA web overview calls all 188 subjects ages 2–12, but the detailed trial report distinguishes 156 ages 2–12 plus 32 older, so the discrepancy should be preserved and the main efficacy number should not be inflated. Primary original facility warnings cannot be assigned to an unnamed alternate facility. Searches found no public alternate identity or inspection acceptance, which means this is missing verification, but it is not proof that no inspection exists. The sources of this information are the EMA website, the FDA website, and the Scholar Rock website. Local SEC direct requests returned a 403 error, which means access is forbidden, but an edgar document proxy recovered the first 60,000 characters of the Q2 report, and the remainder was reviewed via web lines. The FDA 483 report is web readable, but direct download returned a 404 error, which means the page was not found. The origins of the issuer, FDA, and EMA should be counted, but correlated inspection evidence should be considered, and mirrors are not corroboration. No late 2026 readout day was guessed. One placebo straddled the 2024/25 split, so it should be excluded explicitly before publishing holdout metrics.

A news scan found a preregistration for a trading plan. The plan has a three-level question tree. The first level is about timing, which includes the original deadline versus the actual Complete Response Letter, or CRL, which is a letter from the US Food and Drug Administration, and the earliest-decision language. The second level is about economics, which includes funding and commercial aspects. The third level is about trade, which includes inference, execution, and validation. The plan will use daily-session resolution and will not consider social repetition as independent evidence. The plan will also use a fixed diagnostic with a T-20 close to a T-5 close before the original PDUFA, which is a deadline for the US Food and Drug Administration to review a new drug application. The plan will be trained through 2025 and will have a pending event in 2026. If independent events are insufficient, the plan will be labeled as unvalidated. The plan will also use a CLI momentum diagnostic and a separate chronological vectorbt non-event holdout if feasible. The plan will consider fees and slippage of 15/30 basis points per side and will have 5/10/20-day sensitivities for diagnostic purposes only. Simulations will separate observed returns from assumed hazard. The plan has a 43-minute plan and a 45-hard limit, with the last 5 minutes reserved.

A news scan found the link to an FDA briefing for the Catalyst fund, which is for research only and not eligible for approval. The briefing is for a meeting of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee on September 23, 2026. The source of the information is the FDA website. The status of the information is 200, and the date is present in the text. There are no matching links, and the links have a unique code, or sha256, of 4f53cda18c2baa0c0354bb5f9a3ecbe5ed12ab4d8e11ba873c2f11161202b945. The information is not truncated.

A news scan found the following research reminders. On September 6, 2026, at 02:30:38 UTC, reminders were set for upcoming events. The first event is for NKE, which will release its first quarter fiscal year 2027 earnings on October 1, 2026, and have a conference call at 14:00 PT. A research review will be done on October 2, 2026, at 12:30:00Z to compare wholesale and direct demand, markdowns, gross margin, inventories, and cash. If there is improvement, the results will be recorded and an independent event test will be required before taking any risk. If there is weakness, the opportunity will be rejected. There is currently no validated rule to automatically purchase NKE. The next event is for GIS, which will have a Q&A call on September 23, 2026, at 13:00:00Z. A research review will be done on the same day to compare organic volume, pricing, margins, cash, and restructuring savings. If the results are stronger, they will be recorded pending a validated rule. If the results are weaker, the opportunity will be rejected. The review will also consider earlier presentations and preannouncements. There will be no automatic purchase of GIS. Another event is for DATA.L, which will release its half-year results on September 14, 2026, at 12:30:00Z. A research review will be done on the same day to verify the results publication, organic subscriptions, acquisition effects, margins, and cash. If the results are stronger, they will be recorded and the venue, FX, and net strategy will be validated. If the results are weaker, the opportunity will be rejected. If the results have not been released, the source will be rechecked rather than assuming a delay. There will be no automatic entry into DATA.L. The last event is for ET.TO, which will have a Q1 FY2027 conference call on September 14, 2026. A research review will be done on September 15, 2026, at 12:30:00Z to check the actual results notice, software and services mix, and orders.

The automated trading fund manager finished the task around 24 minutes within the planned 43-minute and hard 45-minute limit. The final journal phase was reserved before finishing. There were no proposals, with 49.14 cash and no open or pending items. A fresh screen of 8066 US items from a directory universe of 13154 was conducted, with 346 calendar leads and 6 foreign names, 5 markets, and 10 cryptocurrency pairs, and coverage exclusions were explicit. The HITI had a fixed holdout of 244 with a 3.75545% increase, 63.6364% wins, and a win to loss ratio of 1.50247 to 1.65581%, with a 95% mean confidence interval of -0.73259% to 1.53296%, and stress of +0.38739%. The authorized size is 0. The current Q3 was pre-announced on August 4, but only one historical match was identified, which was not a complete classification proof. The BFRI has an exact PDUFA date of September 28, but there are cash, XL, and financing risks, and HAIN has weak volume. New monitors were set for HITI, HAIN, and BFRI, with 20 armed and none before 04 UTC. The request to set monitors for NKE, GIS, DATA.L, ET.TO, and TSM was rejected due to capacity, with reminders set as job 24 every 720 minutes for 64 runs, but these monitors are not armed. The next run may read the initial output of job 24, and will verify new primary filings and pre-register a future NKE and GIS study, without overfitting HITI. An archive note 279 was made, with 231 parts and 22 files, and a hash of f64feb3a170ea6460c1507dec121192a7b2961fe3b346754a111efd0611d37d7. Lessons 110-112 were noted. There were no venue actions or other fund monitor changes.